1. Howe JR, Merchant NB, Conrad C, et al. The North American Neuroendocrine Tumor Society consensus paper on the surgical management of pancreatic neuroendocrine tumors. Pancreas 2020;49:1–33.

2. Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008;135:1469–1492.

3. de Wilde RF, Edil BH, Hruban RH, Maitra A. Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy. Nat Rev Gastroenterol Hepatol 2012;9:199–208.

4. Hofland J, Falconi M, Christ E, et al. European Neuroendocrine Tumor Society 2023 guidance paper for functioning pancreatic neuroendocrine tumour syndromes. J Neuroendocrinol 2023;35:e13318.

5. Ito T, Sasano H, Tanaka M, et al. Epidemiological study of gastroenteropancreatic neuroendocrine tumors in Japan. J Gastroenterol 2010;45:234–423.

6. Dasari A, Shen C, Halperin D, et al. Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States. JAMA Oncol 2017;3:1335–1342.

7. Kuo EJ, Salem RR. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size. Ann Surg Oncol 2013;20:2815–2821.

8. Manta R, Nardi E, Pagano N, et al. Pre-operative diagnosis of pancreatic neuroendocrine tumors with endoscopic ultrasonography and computed tomography in a large series. J Gastrointestin Liver Dis 2016;25:317–321.

9. Fujimori N, Osoegawa T, Lee L, et al. Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors. Scand J Gastroenterol 2016;51:245–252.

10. Barbe C, Murat A, Dupas B, et al. Magnetic resonance imaging versus endoscopic ultrasonography for the detection of pancreatic tumours in multiple endocrine neoplasia type 1. Dig Liver Dis 2012;44:228–234.

11. Kurita Y, Hara K, Kobayashi N, et al. Detection rate of endoscopic ultrasound and computed tomography in diagnosing pancreatic neuroendocrine neoplasms including small lesions: a multicenter study. J Hepatobiliary Pancreat Sci 2022;29:950–959.

12. Leeds JS, Nayar MK, Bekkali NLH, et al. Endoscopic ultrasound-guided fine-needle biopsy is superior to fine-needle aspiration in assessing pancreatic neuroendocrine tumors. Endosc Int Open 2019;7:E1281–E1287.

13. Hwang HS, Kim Y, An S, et al. Grading by the Ki-67 labeling index of endoscopic ultrasound-guided fine needle aspiration biopsy specimens of pancreatic neuroendocrine tumors can be underestimated. Pancreas 2018;47:1296–1303.

14. Matsumoto K, Kato H. Endoscopic ablation therapy for the pancreatic neoplasms. Dig Endosc 2023;35:430–442.

15. Oleinikov K, Dancour A, Epshtein J, et al. Endoscopic ultrasound-guided radiofrequency ablation: a new therapeutic approach for pancreatic neuroendocrine tumors. J Clin Endocrinol Metab 2019;104:2637–2647.

16. Jürgensen C, Schuppan D, Neser F, Ernstberger J, Junghans U, Stölzel U. EUS-guided alcohol ablation of an insulinoma. Gastrointest Endosc 2006;63:1059–1062.

17. Marasco M, Galasso D, Larghi A, Panzuto F. When should we adopt EUS-guided radiofrequency ablation in pancreatic neuroendocrine tumors? J Clin Med 2023;12:4581.

18. Crinò SF, Napoleon B, Facciorusso A, et al. Endoscopic ultrasound-guided radiofrequency ablation versus surgical resection for treatment of pancreatic insulinoma. Clin Gastroenterol Hepatol 2023;21:2834–2843e2.

19. Larghi A, Rizzatti G, Rimbaş M, Crino SF, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: who should we treat? Endosc Ultrasound 2019;8:220–226.

20. Kos-Kudła B, Castaño JP, Denecke T, et al. European Neuroendocrine Tumour Society (ENETS) 2023 guidance paper for nonfunctioning pancreatic neuroendocrine tumours. J Neuroendocrinol 2023;35:e13343.

21. Rösch T, Lightdale CJ, Botet JF, et al. Localization of pancreatic endocrine tumors by endoscopic ultrasonography. N Engl J Med 1992;326:1721–1726.

22. Attili F, Capurso G, Vanella G, et al. Diagnostic and therapeutic role of endoscopy in gastroenteropancreatic neuroendocrine neoplasms. Dig Liver Dis 2014;46:9–17.

23. Krishna SG, Lee JH. Endosonography in solid and cystic pancreatic tumors. J Interv Gastroenterol 2011;1:193–201.

24. Palazzo M, Napoléon B, Gincul R, et al. Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos). Gastrointest Endosc 2018;87:1481–1488.

25. Ishii T, Katanuma A, Toyonaga H, et al. Role of endoscopic ultrasound in the diagnosis of pancreatic neuroendocrine neoplasms. Diagnostics (Basel) 2021;11:316.

26. Franchellucci G, Andreozzi M, Carrara S, et al. Contrast enhanced EUS for predicting solid pancreatic neuroendocrine tumor grade and aggressiveness. Diagnostics (Basel) 2023;13:239.

27. Itonaga M, Kitano M, Kojima F, et al. The usefulness of EUS-FNA with contrast-enhanced harmonic imaging of solid pancreatic lesions: a prospective study. J Gastroenterol Hepatol 2020;35:2273–2280.

28. Choi JH, Seo DW, Song TJ, et al. Utility of contrast-enhanced harmonic endoscopic ultrasound for the guidance and monitoring of endoscopic radiofrequency ablation. Gut Liver 2020;14:826–832.

29. Jani BS, Rzouq F, Saligram S, et al. Endoscopic ultrasound-guided fine-needle aspiration of pancreatic lesions: a systematic review of technical and procedural variables. N Am J Med Sci 2016;8:1–11.

30. Ginès A, Vazquez-Sequeiros E, Soria MT, Clain JE, Wiersema MJ. Usefulness of EUS-guided fine needle aspiration (EUS-FNA) in the diagnosis of functioning neuroendocrine tumors. Gastrointest Endosc 2002;56:291–296.

31. Asokkumar R, Yung Ka C, Loh T, et al. Comparison of tissue and molecular yield between fine-needle biopsy (FNB) and fine-needle aspiration (FNA): a randomized study. Endosc Int Open 2019;7:E955–E963.

32. Ghabi EM, Habib JR, Shoucair S, et al. Detecting somatic mutations for well-differentiated pancreatic neuroendocrine tumors in endoscopic ultrasound-guided fine needle aspiration with next-generation sequencing. Ann Surg Oncol 2023;30:7720–7730.

33. Mastrosimini MG, Manfrin E, Remo A, et al. Endoscopic ultrasound fine-needle biopsy to assess DAXX/ATRX expression and alternative lengthening of telomeres status in non-functional pancreatic neuroendocrine tumors. Pancreatology 2023;23:429–436.

34. Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology 2020;76:182–188.

35. Jin SY. Recent update of pathology of the pancreatic neuroendocrine tumor. Korean J Med 2011;80:371–377. 36. Chang HM. Consensus guideline for advanced pancreatic neuroendocrine tumor. Korean J Med 2011;80:393–396. 37. Tacelli M, Bina N, Crinò SF, et al. Reliability of grading preoperative pancreatic neuroendocrine tumors on EUS specimens: a systematic review with meta-analysis of aggregate and individual data. Gastrointest Endosc 2022;96:898–908e23.

38. Hill JS, McPhee JT, McDade TP, et al. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival. Cancer 2009;115:741–751.

39. Choi JH, Seo DW, Song TJ, et al. Endoscopic ultrasound-guided radiofrequency ablation for management of benign solid pancreatic tumors. Endoscopy 2018;50:1099–1104.

40. Garg R, Mohammed A, Singh A, et al. EUS-guided radiofrequency and ethanol ablation for pancreatic neuroendocrine tumors: a systematic review and meta-analysis. Endosc Ultrasound 2022;11:170–185.

41. Lakhtakia S. Therapy of pancreatic neuroendocrine tumors: fine needle intervention including ethanol and radiofrequency ablation. Clin Endosc 2017;50:546–551.

42. Marx M, Godat S, Caillol F, et al. Management of non-FUNCTIONAL pancreatic neuroendocrine tumors by endoscopic ultrasound-guided radiofrequency ablation: Retrospective study in two tertiary centers. Dig Endosc 2022;34:1207–1213.

43. So H, Ko SW, Shin SH, et al. Comparison of EUS-guided ablation and surgical resection for nonfunctioning small pancreatic neuroendocrine tumors: a propensity score-matching study. Gastrointest Endosc 2023;97:741–751e1.

44. Zhang WY, Li ZS, Jin ZD. Endoscopic ultrasound-guided ethanol ablation therapy for tumors. World J Gastroenterol 2013;19:3397–3403.

45. Aslanian H, Salem RR, Marginean C, Robert M, Lee JH, Topazian M. EUS-guided ethanol injection of normal porcine pancreas: a pilot study. Gastrointest Endosc 2005;62:723–727.

46. Park DH, Choi JH, Oh D, et al. Endoscopic ultrasonography-guided ethanol ablation for small pancreatic neuroendocrine tumors: results of a pilot study. Clin Endosc 2015;48:158–164.

47. Yang D, Inabnet WB 3rd, Sarpel U, DiMaio CJ. EUS-guided ethanol ablation of symptomatic pancreatic insulinomas. Gastrointest Endosc 2015;82:1127.

48. Paik WH, Seo DW, Dhir V, Wang HP. Safety and efficacy of EUS-guided ethanol ablation for treating small solid pancreatic neoplasm. Medicine (Baltimore) 2016;95:e2538.

49. Choi JH, Park DH, Kim MH, et al. Outcomes after endoscopic ultrasound-guided ethanol-lipiodol ablation of small pancreatic neuroendocrine tumors. Dig Endosc 2018;30:652–658.

50. Matsumoto K, Kato H, Kawano S, et al. Efficacy and safety of scheduled early endoscopic ultrasonography-guided ethanol reinjection for patients with pancreatic neuroendocrine tumors: prospective pilot study. Dig Endosc 2020;32:425–430.

51. Yan Z, Zhu C, Wu X, et al. A single-center experience on endoscopic ultrasonography-guided ethanol ablation of insulinomas. Pancreatology 2023;23:98–104.

52. Mele C, Brunani A, Damascelli B, et al. Non-surgical ablative therapies for inoperable benign insulinoma. J Endocrinol Invest 2018;41:153–162.

53. Levy MJ, Thompson GB, Topazian MD, Callstrom MR, Grant CS, Vella A. US-guided ethanol ablation of insulinomas: a new treatment option. Gastrointest Endosc 2012;75:200–206.

54. Yousaf MN, Ehsan H, Muneeb A, et al. Role of radiofrequency ablation in the management of unresectable pancreatic cancer. Front Med (Lausanne) 2021;7:624997.

55. Gazelle GS, Goldberg SN, Solbiati L, Livraghi T. Tumor ablation with radio-frequency energy. Radiology 2000;217:633–646.

56. Armellini E, Crinò SF, Ballarè M, Occhipinti P. Endoscopic ultrasound-guided radiofrequency ablation of a pancreatic neuroendocrine tumor. Endoscopy 2015;47(Suppl 1 UCTN):E600–E601.

57. Gollapudi LA, Tyberg A. EUS-RFA of the pancreas: where are we and future directions. Transl Gastroenterol Hepatol 2022;7:18.

58. Kim HJ, Seo DW, Hassanuddin A, et al. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc 2012;76:1039–1043.

59. Khoury T, Sbeit W, Fusaroli P, et al. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine neoplasms: Systematic review and meta-analysis. Dig Endosc 2024;36:395–405.

60. Borrelli de Andreis F, Boškoski I, Mascagni P, et al. Safety and efficacy of endoscopic ultrasound-guided radiofrequency ablation for pancreatic insulinoma: a single-center experience. Pancreatology 2023;23:543–549.

61. Lakhtakia S, Ramchandani M, Galasso D, et al. EUS-guided radiofrequency ablation for management of pancreatic insulinoma by using a novel needle electrode (with videos). Gastrointest Endosc 2016;83:234–239.

62. Paiella S, De Pastena M, D’Onofrio M, et al. Palliative therapy in pancreatic cancer-interventional treatment with radiofrequency ablation/irreversible electroporation. Transl Gastroenterol Hepatol 2018;3:80.

63. Pai M, Habib N, Senturk H, et al. Endoscopic ultrasound guided radiofrequency ablation, for pancreatic cystic neoplasms and neuroendocrine tumors. World J Gastrointest Surg 2015;7:52–59.

64. Barthet M, Giovannini M, Lesavre N, et al. Endoscopic ultrasound-guided radiofrequency ablation for pancreatic neuroendocrine tumors and pancreatic cystic neoplasms: a prospective multicenter study. Endoscopy 2019;51:836–842.

65. Dancour A, Benson A, Epshtein J, et al. Endoscopic ultrasound guided radiofrequency ablation of insulinomas is safe and effective. Gastrointest Endosc 2019;89(6 Suppl):AB323.

66. De Nucci G, Mandelli ED, Redaelli D, et al. Endoscopic ultrasound guided radiofrequency ablation for neuroendocrine tumors: a single center case series. Endoscopy 2019;51:S57. 67. Furnica RM, Deprez P, Maiter D, Vandeleene B, Borbath I. Endoscopic ultrasound-guided radiofrequency ablation: an effective and safe alternative for the treatment of benign insulinoma. Ann Endocrinol (Paris) 2020;81:567–571.

68. Marx M, Trosic-Ivanisevic T, Caillol F, et al. EUS-guided radiofrequency ablation for pancreatic insulinoma: experience in 2 tertiary centers. Gastrointest Endosc 2022;95:1256–1263.

69. Imperatore N, de Nucci G, Mandelli ED, et al. Endoscopic ultrasound-guided radiofrequency ablation of pancreatic neuroendocrine tumors: a systematic review of the literature. Endosc Int Open 2020;8:E1759–E1764.

70. Haen SP, Pereira PL, Salih HR, Rammensee HG, Gouttefangeas C. More than just tumor destruction: immunomodulation by thermal ablation of cancer. Clin Dev Immunol 2011;2011:160250.